orforglipron vs oral semaglutide Eli Lilly's new anti-obesity pill Orforglipron shows promise

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral semaglutide, made by Novo Nordisk, suggests the former pill may have the edge

21.74

★★★★☆4.8 (126)

The Rise of Oral Obesity Therapies: Semaglutide and Orforglipron

26.38

★★★★★4.9 (98)

Very exciting times! , Two oral GLP-1 options are now on the table—and they are not the same., Oral semaglutide vs orforglipron:, Orforglipron (non-peptide, no fasting required), – ~12.4% weight loss

23.16

★★★★★5.0 (157)

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

23.36

★★★★★4.7 (84)

Orforglipron Outperforms Oral Semaglutide in Head-to-Head T2D Trial

22.49

★★★★★4.9 (203)

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

22.35

★★★★★5.0 (176)

Wegovy Sulfur Burps: Why They Happen and How to Treat Them

20.24

★★★★★4.8 (132)